Physician profile
Peter Baydu
NPI 1851961031
$2,633.99
in general payments reported to CMS, 2019-2025
34 companies · $715 in 2025
The $715 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $806 · 2023: $192 · 2024: $355 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883 · Education: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.14 |
| Education | $379.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $304.04 | 2021-2025 | |
| Amgen INC. | $298.11 | 2021-2025 | Vectibix |
| Janssen Biotech, INC. | $287.66 | 2024-2025 | Akeega, Erleada, Carvykti |
| Teva Pharmaceuticals USA, INC. | $222.61 | 2021-2022 | |
| Abbvie INC. | $174.62 | 2022-2024 | |
| Incyte Corporation | $173.51 | 2022-2023 | |
| Daiichi Sankyo INC. | $150.44 | 2024-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Reblozyl |
| Seagen INC. | $95.00 | 2025 | |
| Myovant Sciences INC. | $81.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $80.91 | 2023 | Lynparza |
| Biohaven Pharmaceutical Holding Company LTD. | $79.92 | 2022 | |
| Tempus Ai, INC | $59.84 | 2024 | |
| Eisai INC. | $50.12 | 2021 | |
| Sobi, INC | $43.48 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $43.00 | 2022 | |
| Merz Pharmaceuticals, LLC | $38.73 | 2021-2022 | |
| Gilead Sciences, INC. | $34.04 | 2025 | Trodelvy |
| Amneal Pharmaceuticals LLC | $33.87 | 2021-2022 | |
| Biogen, INC. | $27.94 | 2021 | |
| Pfizer INC. | $22.89 | 2024 | |
| Avion Pharmaceuticals | $20.47 | 2022 | |
| Sk Life Science, INC. | $19.32 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.27 | 2022 | |
| Mdd US Operations, LLC | $18.78 | 2022 | |
| Currax Pharmaceuticals LLC | $18.56 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.11 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.41 | 2021 | |
| Celgene Corporation | $14.00 | 2022 | |
| Ucb, INC. | $13.98 | 2021 | |
| Almatica Pharma LLC | $13.79 | 2021 | |
| Biodelivery Sciences International, INC. | $13.17 | 2021 | |
| Myriad Genetic Laboratories, INC. | $13.11 | 2023 | Myrisk |
| Biohaven Pharmaceuticals, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Baydu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.